Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug glucuronidation in humans.

J O Miners1, P I Mackenzie

  • 1Department of Clinical Pharmacology, Flinders Medical Centre, Adelaide, South Australia.

Pharmacology & Therapeutics
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance.

Clinical pharmacology and therapeutics·2017
Same author

Haemodynamic effects of parenteral vs. enteral paracetamol in critically ill patients: a randomised controlled trial.

Anaesthesia·2016
Same author

Steroid UDP glucuronosyltransferases.

The Journal of steroid biochemistry and molecular biology·2012
Same author

Liver-enriched transcription factors and their role in regulating UDP glucuronosyltransferase gene expression.

Current drug metabolism·2008
Same author

Comparative homology modeling of human cytochrome P4501A1 (CYP1A1) and confirmation of residues involved in 7-ethoxyresorufin O-deethylation by site-directed mutagenesis and enzyme kinetic analysis.

Archives of biochemistry and biophysics·2007
Same author

The glucuronidation of Delta4-3-Keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6alpha- and 21-hydroxyprogesterone are selective substrates for UGT2B7.

Drug metabolism and disposition: the biological fate of chemicals·2006
Same journal

C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.

Pharmacology & therapeutics·2026
Same journal

The CircRNA/miRNA axis in breast cancer: From molecular mechanisms to clinical translation.

Pharmacology & therapeutics·2026
Same journal

Glymphatic-meningeal lymphatic dysfunction in epilepsy: novel mechanistic insights and therapeutic avenues.

Pharmacology & therapeutics·2026
Same journal

The neurovascular unit under siege: Molecular mechanisms and potential drug target for cerebral edema.

Pharmacology & therapeutics·2026
Same journal

A-type potassium channels in pain signaling: Fundamental mechanisms and pathophysiological roles.

Pharmacology & therapeutics·2026
Same journal

GPCR crosstalk beyond obligate dimerisation: Effector coincidence detection, compartmentation, and pharmacological implications.

Pharmacology & therapeutics·2026
See all related articles

Glucuronidation, a key drug metabolism process, involves UDP-glucuronosyltransferase enzymes. Various factors like age, diet, and genetics influence this crucial pathway for drug clearance.

Area of Science:

  • Pharmacology and Toxicology
  • Drug Metabolism and Pharmacokinetics

Background:

  • Glucuronidation is a primary metabolic pathway for numerous drugs in humans.
  • This process involves the conjugation of xenobiotics with glucuronic acid, facilitating their elimination.
  • The UDP-glucuronosyltransferase (UGT) enzyme family catalyzes drug glucuronidation.

Purpose of the Study:

  • To review the significance of UDP-glucuronosyltransferase enzymes in drug metabolism.
  • To explore factors influencing drug glucuronidation and subsequent pharmacokinetics.
  • To highlight the complexity of drug metabolism influenced by various physiological and environmental factors.

Main Methods:

  • Review of existing literature on drug metabolism and UDP-glucuronosyltransferase activity.
  • Analysis of factors affecting drug pharmacokinetics related to glucuronidation.

Related Experiment Videos

  • Synthesis of information on isozyme specificity and regulatory mechanisms.

    • Main Results:

    • Multiple UDP-glucuronosyltransferase isozymes contribute to drug glucuronidation, each with unique substrate specificities.
    • Pharmacokinetics of glucuronidated drugs are significantly influenced by factors including age, smoking, diet, disease, drug interactions, ethnicity, genetics, and hormones.
    • These factors likely exert their effects by modulating the activity of specific UGT isozymes.

    Conclusions:

    • Drug glucuronidation is a complex process mediated by a diverse family of UDP-glucuronosyltransferase enzymes.
    • Understanding the influence of various factors on UGT activity is critical for predicting drug response and optimizing pharmacotherapy.
    • Further research is needed to fully elucidate the roles and regulation of individual UGT isozymes.